Oleoylethanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation

Pharmacological Research

Volumn 61, Issue 5, 2010, Pages 379-384

  Soria Gomez E ^a,b   Guzman K ^a,c   Pech Rueda, O ^a   Montes Rodriguez C J ^a,d   Cisneros, M ^a   Prospero Garcia O ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^d UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

C Fos; Feeding behavior; Lateral hypothalamus; Oleoylethanolamide; Periaqueductal gray matter; PPARs; REM sleep

Indexed keywords

N OLEOYLETHANOLAMINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEEDING BEHAVIOR; FOOD INTAKE; HYPOTHALAMUS; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REM SLEEP; SLEEP WAKING CYCLE;

EID: 77950627161     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.01.010     Document Type: Article

References (59)

1. Fu J., Astarita G., Gaetani S., Kim J., Cravatt B.F., Mackie K., et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal intestine. J Biol Chem 2007, 282:1518-1528.
2. Fu J., Kim J., Oveisi F., Astarita G., Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 2008, 295:R45-R50.
3. Schwartz G.J., Fu J., Astarita G., Li X., Gaetani S., Campolongo P., et al. The lipid messenger OEA links dietary fat intake with satiety. Cell Metab 2008, 8:281-288.
4. Rodríguez de Fonseca F., Navarro M., Gómez R., Escuredo L., Nava F., Fu J., et al. An anorexic lipid mediator regulated by feeding. Nature 2001, 414:209-212.
5. Petersen G., Sorensen C., Schmid P.C., Artmann A., Tang-Christensen M., Hansen S.H., et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 2006, 1761:143-150.
6. Gaetani S., Oveisi F., Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology 2003, 28:1311-1316.
7. Nielsen M.J., Petersen G., Astrup A., Hansen H. Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 2004, 45:1027-1029.
8. Oveisi F., Gaetani S., Tai-Pang Eng K., Piomelli D. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res 2004, 49:461-466.
9. Fu J., Oveisi F., Gaetani S., Lin E., Piomelli D. Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005, 48:1147-1153.
10. Guzmán M., Lo Verme J., Fu J., Oveisi F., Blázquez C., Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). J Biol Chem 2004, 279:27849-27854.
11. Cani P.D., Lasa Montoya M., Neyrinck A.M., Delzenne N.M., Lambert D.M. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004, 92:757-761.
12. González-Yanez C., Serrano A., Bermúdez-Silva F.J., Hernández-Dominguez M., Páez-Ochoa M.A., Rodríguez de Fonseca F., et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 2005, 289:E923-E929.
13. Wang X., Miyares R.L., Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 2005, 564(2):541-547.
14. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodriguez de Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003, 425:90-93.
15. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
16. Rosen P.D. Energy balance: a new role for PPARα. Curr Biol 2003, 13:R961-R963.
17. Van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharm Res 2004, 21:1531-1538.
18. Diradourian C., Girard J., Pégorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005, 87:33-38.
19. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94.
20. Chakravarthy M.V., Zhu Y., López M., Yin L., Wozniak D.F., Coleman T., et al. Brain fatty acid synthase activates PPARα to maintain energy homeostasis. J Clin Invest 2007, 117:2539-2552.
21. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol 2005, 26:244-251.
22. Ahern G.P. Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 2003, 278:30429-30434.
23. Almasí R., Szöke E., Bölcskei K., Varga A., Riedl Z., Sándor Z., et al. Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci 2008, 82:644-651.
24. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C.T., Gardner L.S., Griffin G., et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006, 3:167-175.
25. Richardson D., Ortori C.A., Chapman V., Kendall D.A., Barrett D.A. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem 2007, 360:216-226.
26. Murillo-Rodríguez E., Désarnaud F., Prospéro-García O. Diurnal variation of arachidonoylethanolamide, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 2006, 79:30-37.
27. Ganjavi H., Shapiro C.M. Hypocretin/orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci 2007, 19:413-419.
28. Sutcliffe J.G., de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 2000, 62:161-168.
29. Horvath T.L., Gao X.B. Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. Cell Metab 2005, 1:279-286.
30. Sakurai T. Orexin: a link between energy homeostasis and adaptive behavior. Curr Opin Clin Nutr Metab Care 2003, 6:353-360.
31. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 2008, 28:13985-13994.
32. Shirai H., Oishi K., Kudo T., Shibata S., Ishida N. PPARα is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders. Biochem Biophys Res Commun 2007, 357:679-682.
33. Chikahisa S., Tominaga K., Kawai T., Kitaoka K., Oishi K., Ishida N., et al. Bezafibrate, a peroxisome proliferators-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. Endocrinology 2008, 149:5262-5271.
34. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
35. Soria-Gómez E., Matias I., Rueda-Orozco P.E., Cisneros M., Petrosino S., Navarro L., et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 2007, 151:1109-1116.
36. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999, 143:315-317.
37. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature 1998, 395:381-383.
38. Murillo-Rodríguez E., Millán-Aldaco D., Di Marzo V., Drucker-Colín R. The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience 2008, 157:1-11.
39. Murillo-Rodríguez E., Cabeza R., Méndez-Díaz M., Navarro L., Prospéro-García O. Anandamide-induced sleep is blocked by SR14151617A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 2001, 12:2131-2136.
40. De Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998, 95:322-327.
41. Skofitsch G., Jacobowitz D.M., Zamir N. Immunohistochemical localization of a melanin concentrating hormone-like peptide in the rat brain. Brain Res Bull 1985, 15:635-649.
42. Tritos N.A., Maratos-Flier E. Two important systems in energy homeostasis: melanocortins and melanin-concentrating hormone. Neuropeptides 1999, 33:339-349.
43. Shi Y. Beyond skin color: emerging roles of melanin-concentrating hormone in energy homeostasis and other physiological functions. Peptides 2004, 25:1605-1611.
44. Sakurai T. Roles of orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol Disord Drug Targets 2006, 5:313-325.
45. Mungs M., Mignot E. Hypocretin/orexin, sleep and narcolepsy. Bioessays 2001, 25:397-408.
46. Kilduff T.S., Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000, 23:359-365.
47. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell 1999, 98:409-412.
48. Van den Pol A.N. Narcolepsy: a neurodegenerative disease of the hypocretin system?. Neuron 2000, 27:415-418.
49. Verret L., Goutagny R., Fort P., Cagnon L., Salvert D., Leger L., et al. A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 2003, 9:4-16.
50. Modirrousta M., Mainville L., Jones B.E. Orexin and MCH neurons express c-Fos differentially after sleep deprivation vs. recovery and bear different adrenergic receptors. Eur J Neurosci 2005, 21:2807-2816.
51. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
52. Lee M.G., Hassani O.K., Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005, 25:6716-6720.
53. Lin J.S., Sakai K., Vanni-Mercier G., Jouvet M. A critical role of the posterior hypothalamus in the mechanism of wakefulness determined by microinjection of muscimol in freely moving cats. Brain Res 1989, 479:225-240.
54. Will M.J., Franzblau E.B., Kelley A.E. Nucleus accumbens μ-opioids regulate intake of a high-fat diet via activation of a distributed brain network. J Neurosci 2003, 23:2882-2888.
55. Fuller P.M., Saper C.B., Lu J. The pontine REM switch: past and present. J Physiol 2007, 584:735-741.
56. Lu J., Sherman D., Devor M., Saper C.B. A putative flip-flop switch for control of REM sleep. Nature 2006, 441:589-594.
57. Koethe D., Schreiber D., Giuffrida A., Mauss C., Faulhaber J., Heydenreich B., et al. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. J Neural Transm 2009, 116:301-305.
58. Horne J. REM sleep, energy balance and " optimal foraging" Neurosci Biobehav Rev 2009, 33:466-474.
59. Krueger J.M., Rector D.M., Roy S., Van Dongen H.P., Belenky G., Panksepp J. Sleep as a fundamental property of neuronal assemblies. Nat Rev Neurosci 2008, 9:910-919.